Segulah Medical Acceleration AB (SMA) has invested in the cancer liquid biopsy and genomic testing company SAGA Diagnostics’ oversubscribed SEK 106 million Series A2 equity financing round. SMA was represented by KANTER in the investment.
Segulah Medical Acceleration AB (SMA) has invested in the cancer liquid biopsy and genomic testing company SAGA Diagnostics’ oversubscribed SEK 106 million Series A2 equity financing round. SMA was represented by KANTER in the investment.